Clinical trials set on drug to treat fragile X syndrome

11/2/2009 | Disability Scoop

Researchers are set to begin clinical testing of STX107, a drug to treat fragile X syndrome, which is believed to be the most common cause of intellectual disabilities. After initial safety testing on healthy adults, researchers will test whether the drug is able to restore normal brain connections in people who have fragile X. The inherited condition is found in 1 in 6,000 girls and 1 in 4,000 boys.

View Full Article in:

Disability Scoop

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
San Francisco Unified is Accepting Applications for 2015-16!
San Francisco Unified School District
San Francisco, CA
Director of Professional Services
Engaging Schools, Inc.
Cambridge, MA
Principal at Emerson Academy of Dayton
National Heritage Academies
Dayton, OH
Program Officer, Teacher Development
Knowles Science Teaching Foundation
Moorestown, NJ
Senior Researcher (8194)
American Institute for Researcher
Washington, DC